Studies on PML-RARA AML have identified the positive expression of CD33, CD13, and CD19 antigens; the absence of HLA-DR expression; and low-frequency CD7, CD11b, and CD14 expression. This evidence concerns the gene CD19 and acute myeloid leukemia.